256 related articles for article (PubMed ID: 22313456)
1. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
[No Abstract] [Full Text] [Related]
2. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
5. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
Lai S; Venugopal P; Leslie W
Clin Adv Hematol Oncol; 2012 Feb; 10(2):134-6. PubMed ID: 22402359
[No Abstract] [Full Text] [Related]
6. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
[No Abstract] [Full Text] [Related]
10. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study.
Jung HA; Park S; Cho JH; Kim S; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2012 Nov; 91(11):1747-56. PubMed ID: 22739576
[TBL] [Abstract][Full Text] [Related]
11. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
Manabe M; Hayashi Y; Yoshii Y; Mukai S; Sakamoto E; Kanashima H; Nakao T; Hayama T; Fukushima H; Inoue T; Yamane T; Teshima H
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1733-5. PubMed ID: 23152030
[TBL] [Abstract][Full Text] [Related]
12. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
Olszewski AJ; Winer ES; Castillo JJ
Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
14. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.
Coutinho R; Pria AD; Gandhi S; Bailey K; Fields P; Cwynarski K; Wilson A; Papanastasopoulos P; Tenant-Flowers M; Webb A; Burns F; Marcus RE; Orkin C; Montoto S; Bower M
AIDS; 2014 Mar; 28(5):689-97. PubMed ID: 24418826
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
16. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial.
Mounier N; Heutte N; Thieblemont C; Briere J; Gaulard P; Feugier P; Ghesquieres H; Van Den Neste E; Robu D; Tilly H; Bouabdallah R; Safar V; Coiffier B;
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):151-4. PubMed ID: 22301063
[No Abstract] [Full Text] [Related]
17. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
18. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
19. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
20. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
